| Entry |
|
|---|
| Name |
VHL mutation to HIF-2 signaling pathway
|
|---|
| Definition |
(VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO) |
|---|
| Expanded |
(7428v3+9978+6921+6923+8453) // 2034 == 405 => (7422,3576,6513,2056) |
|---|
| Class |
|
|---|
| Type |
Variant
|
|---|
| Pathway |
|
|---|
| Disease |
| H00559 | von Hippel-Lindau syndrome |
|
|---|
| Gene |
| 7428 | VHL; von Hippel-Lindau tumor suppressor |
| 2034 | EPAS1; endothelial PAS domain protein 1 |
| 405 | ARNT; aryl hydrocarbon receptor nuclear translocator |
| 7422 | VEGFA; vascular endothelial growth factor A |
| 3576 | CXCL8; C-X-C motif chemokine ligand 8 |
| 6513 | SLC2A1; solute carrier family 2 member 1 |
|
|---|
| Reference |
|
|---|
| Authors |
Choi WW, Boland JL, Kalola A, Lin J |
|---|
| Title |
Belzutifan (MK-6482): Biology and Clinical Development in Solid Tumors. |
|---|
| Journal |
|
|---|
| Reference |
|
|---|
| Authors |
Chan KH, Li N, Lador R, Amsbaugh M, Gonzalez A, Cen P |
|---|
| Title |
Belzutifan, HIF-2alpha Inhibitor, and Clear Cell Renal Cell Carcinoma With Somatic Von-Hippel-Lindau Loss-of-Function Mutation. |
|---|
| Journal |
|
|---|
| LinkDB |
|
|---|
